Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4005130 · 3 trials · 4 indications
A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY4005130 | EXPERIMENTAL | LY4005130 administered intravenously (IV) |
| Placebo | PLACEBO_COMPARATOR | Placebo administered IV |
| LY4005130 Part A (SAD) SC | EXPERIMENTAL | A single-ascending dose of LY4005130 administered subcutaneously (SC) |
| Placebo Part A (SAD) SC | PLACEBO_COMPARATOR | Placebo administered SC |
| LY4005130 Part A (SAD) IV | EXPERIMENTAL | A single-ascending dose of LY4005130 administered intravenously (IV) |
| Placebo Part A (SAD) IV | PLACEBO_COMPARATOR | Placebo administered IV |
| LY4005130 Part A (SAD) Optional | EXPERIMENTAL | A single-ascending dose of LY4005130 administered either SC or IV depending on emerging data from earlier cohorts |
| Placebo Part A (SAD) Optional | PLACEBO_COMPARATOR | A single-ascending dose of placebo administered either SC or IV depending on emerging data from earlier cohorts |
| LY4005130 Part B (MAD) IV | EXPERIMENTAL | Multiple-ascending doses of LY4005130 administered IV |
| Placebo Part B (MAD) IV | PLACEBO_COMPARATOR | Placebo administered IV |
| LY4005130 Part B (MAD) SC or IV | EXPERIMENTAL | Multiple-ascending doses of LY4005130 administered either SC or IV depending on emerging data from earlier cohorts |
| Placebo Part B (MAD) SC or IV | PLACEBO_COMPARATOR | Multiple-ascending doses of placebo administered either SC or IV depending on emerging data from earlier cohorts |
| LY4005130 Part B (MAD) Optional | EXPERIMENTAL | Multiple-ascending doses of LY4005130 administered either SC or IV depending on emerging data from earlier cohorts |
| Placebo Part B (MAD) Optional | PLACEBO_COMPARATOR | Multiple-ascending doses of placebo administered either SC or IV depending on emerging data from earlier cohorts |
| Name | Type | Description |
|---|---|---|
| LY4005130 | DRUG | Administered IV |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: * Have severe Alopecia Areata (AA) that meets all of the following criteria: * Hair loss encompassing ≥50% and ≤90% of the scalp, as measured by Severity of Alopecia Tool (SALT) score * The duration of the current episode of severe AA is at least 6 months and does not excee...
LY4005130 is an investigational small molecule being developed by Eli Lilly and Company for dermatology conditions. It is being studied in Phase 2 clinical trials for severe alopecia areata (hair loss) and non-segmental vitiligo. The drug is also being evaluated in a completed Phase 1 study in healthy participants.
LY4005130 is a small molecule developed by Eli Lilly and Company. The specific molecular target of LY4005130 has not been disclosed in the available information. The drug is being investigated for its potential to treat alopecia areata and vitiligo, both of which are autoimmune-related skin conditions.
LY4005130 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The drug is currently in Phase 2 clinical development for dermatology indications including alopecia areata and vitiligo.
LY4005130 is currently in Phase 2 clinical development. Eli Lilly and Company is conducting two Phase 2 trials for the drug, one in severe alopecia areata and another in non-segmental vitiligo. A Phase 1 study in healthy participants has been completed. LY4005130 is investigational and not yet approved.
LY4005130 is being studied in three clinical trials. NCT06690996 is a completed Phase 1 study in healthy participants. NCT07533006 is a recruiting Phase 2 trial in adults with severe alopecia areata. NCT07533019 is a recruiting Phase 2 trial in adults with non-segmental vitiligo. All trials are randomized, double-blind, and placebo-controlled.
LY4005130 is not FDA approved. It is an investigational drug currently in Phase 2 clinical trials for alopecia areata and vitiligo, developed by Eli Lilly and Company. The drug has completed a Phase 1 study in healthy participants, but it remains in clinical development and has not received regulatory approval.